AETERNA ZENTARIS INC (AEZS.CA) Stock News

Canada - TSX:AEZS - CA0079756007 - Common Stock

4.12 CAD

+0.06 (+1.48%)

Last: 11/22/2024, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AEZS.CA Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

a year ago - By: Ceapro Inc. - Mentions: CZO.CA AEZS

Aeterna Zentaris and Ceapro Complete Merger Transaction

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris and Ceapro Complete Merger Transaction

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Reports First Quarter 2024 Financial Results

a year ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Announces Effective Date of Share Consolidation

2 years ago - By: Ceapro Inc. - Mentions: CZO.CA AEZS

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

2 years ago - By: Ceapro Inc.; Aeterna Zentaris Inc. - Mentions: CZO.CA AEZS

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

2 years ago - By: Ceapro Inc. - Mentions: CZO.CA AEZS

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Reports Second Quarter 2023 Financial Results

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

2 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Reports First Quarter 2023 Financial Results

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Reports Third Quarter 2022 Financial Results

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Announces Effective Date of Share Consolidation

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists

3 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

4 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight

4 years ago - By: Aeterna Zentaris Inc - Mentions: AEZS

Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity